Datasheet for ABIN2946770

CREB1 ELISA Kit

1 Publication

Go to Product page

Overview

Quantity:	96 tests
Target:	CREB1
Reactivity:	Mouse
Method Type:	Sandwich ELISA
Detection Range:	0.156 ng/mL - 10 ng/mL
Minimum Detection Limit:	0.156 ng/mL
Application:	ELISA

Product Details

Purpose:	Mouse Cyclic AMP Response Element Binding Protein ELISA Kit is an ELISA Kit against Cyclic AMP Response Element Binding Protein.
Sample Type:	Plasma, Serum
Analytical Method:	Quantitative
Detection Method:	Colorimetric
Sensitivity:	0.1 ng/mL

Target Details

Target:	CREB1
Alternative Name:	Cyclic AMP Response Element Binding Protein (CREB1 Products)
Pathways:	TLR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin

Target Details

	Signaling Pathway, Thyroid Hormone Synthesis, Activation of Innate immune Response, Myometrial Relaxation and Contraction, Regulation of Cell Size, Toll-Like Receptors Cascades, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, Positive Regulation of fat Cell Differentiation

Application Details

Application Notes:	Stability: The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5 % within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout. Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user. Standard Form: Lyophilized
Plate:	Pre-coated
Restrictions:	For Research Use only

Handling

Storage:	4 °C/-20 °C
Storage Comment:	Upon receipt, store the kit according to the storage instruction in the kit's manual.
Expiry Date:	6 months

Publications

Product cited in:	Platania, Maisto, Trotta, DAmico, Rossi, Gesualdo, DAmico, Balta, Herman, Hermenean, Ferraraccio, Panarese, Drago, Bucolo: "Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach." in: **British journal of pharmacology**, Vol. 176, Issue 13, pp. 2179-2194, (2019) (PubMed).